National Healthcare Facility Rx Diversion Summit Minneapolis, MN

We're sorry, but all tickets sales have ended because the event is expired.
  • NADDI Healthcare Facility Rx Diversion Summit
    April 24, 2018
    8:30 am - 5:00 pm
  • NADDI Healthcare Facility Rx Diversion Summit
    April 25, 2018
    8:00 am - 5:00 pm

Hilton Minneapolis/St. Paul Airport
Mall of America

NADDI Conference Room Rate
$139.00 Run of the House

Reservations can be made by calling the hotel directly at 952-854-2100
The extended cutoff date to receive the special conference rate is April 5, 2018

Online reservations can also be made at the below link, please cut and paste the link into your browser

Thank You to our Summit Sponsors!

Gold Sponsors

Kit Check

Silver Sponsor

Verde Technologies

For sponsorship and exhibitor opportunities, please contact Charlie Cichon at

NADDI membership is not required for attendance, but you must qualify for membership to attend any NADDI sponsored event.

The Summit will provide 9.5 hrs AMA PRA Category 1 Credits™
and ANCC and ACPE contact hours

Keynote – Senator Amy Klobuchar – Video Address

Medora Witwer, MPH, CIC Epidemiologist
Minnesota Department of Health
Drug diversion is universal in healthcare facilities across the United States. Implications for facilities and patient care can vary, but some of the worst consequences of drug diversion can be the spread of infectious disease. Medora Witwer outlines some outbreak investigations associated with drug diversion conducted by the Minnesota Department of Health, as well as signs of drug diversion, reasons health care workers are at particular risk for drug addiction, and provides tools that can guide facilities through development of a drug diversion program.

Tim Munzing, MD – Kaiser Permanente
Family Medicine Residency Program Director- Kaiser Permanente Orange County Medical Expert Consultant – DEA, Medical Board of California, FBI and multiple other law enforcement agencies.

Public Policy and Diversion Prevention:
What is Happening at the Federal and State Levels?
Panel hosted by the Collaborative for Effective Prescription Opioid Policies (CEPOP,

Prescription Monitoring Programs: New Developments in PDMPs
Barbara A. Carter

President, National Association of State Controlled Substances (NASCA)
Barbara Carter manages the Prescription Monitoring Program Minnesota’s Board of Pharmacy. Ms. Carter received her certification in project management from the University of Minnesota and her certification in data processing & programming from Hennepin Technical College. Ms. Carter currently serves on the Executive Board for the National Association of State Controlled Substance Authority’s (NASCSA) and chairs their PMP Committee. Additionally, Ms. Carter serves on the National Association of Boards of Pharmacy, PMP InterConnect Steering Committee, and is a “Committed Member” of the Office of the National Coordinator’s Standards and Interoperability Framework PDMP and Health IT Integration Initiative. Ms. Carter previously served as Secretary for the Alliance of States with Prescription Monitoring Programs and worked for the Minnesota Department of Human Services aligning business needs with technology and the Minnesota Department of Health as the State Registrar of Vital Statistics.

Larry Houck, JD – Hyman, Phillips and McNamara PC
Larry K. Houck provides counsel on regulatory and enforcement actions by the DEA. His career encompasses over 30 years of conducting investigations and negotiating on behalf of both the government and industry. Mr. Houck focuses on controlled substances, prescription drugs, and regulated chemicals, helping clients navigate federal and state licensing, registration, and compliance issues.

Rodrigo Garcia, APN, MBA, MSN, CRNA, ACIT
Executive Program and Professional Reentry Director
Parkdale Center for Professionals
Rodrigo has been a direct care provider in the health care field for more than 20 years, with experience in emergency management, intensive care, surgical services, and anesthesia. He is currently a member of the Indiana Office of the Attorney General task force; a delegate to the National Safety Council, and has held faculty positions at Evanston Northwestern School of Anesthesia, Ivy Technical Community College – Nursing Department, and Valparaiso University School of Nursing. Rodrigo has extensive experience in the field of addiction, treatment, management, advocacy, and recovery of the highly-accountable recovering professional.

Kristen Jurackovick, Narcotic Control Coordinator
University of Wisconsin Health
Kristen is the Internal Auditor of Narcotic Control for UW-Health where she has been working to promote patient and employee safety through her passion of preventing and detecting drug diversion.

Russell Nix, Drug Diversion Specilist
Regulatory Compliance and Privacy
Piedmont Athens (GA) Regional
Over 18 years of law enforcement and security experience, including design, implementation, and instruction of training programs for drug diversion prevention, defensive tactics, policy / law compliance and
personal safety.

Marc Myer, MD Medical Director for Adult Services
Minnesota and Healthcare Professionals Program Director

Halzelden Betty Ford Foundation
Dr. Myer is a diplomat of the American Board of Addiction Medicine and previously worked as a family physician. An active member of the American and Minnesota societies of addiction medicine, Dr. Myer alos serves on the executive committee of Physicians Serving Physicians in Minnesota.

Information Sharing / Panel Discussion
JoAnne Myhre, CPhT, BA
Drug Diversion Program Manager Pharmacy/Compliance Services • Allina Health

Chuck Grinstead, Assistant Special Agent in Charge

FDA OCI Kansas City Field Office

Melissa Culbreth, MSSW, LMSW
Director, Medication Compliance
HCA | Clinical Services Group

Lorri Hall, Security Manager
Mayo Clinic (FL)

“The scope and frequency of drug diversion is almost impossible to grasp, due in large part to how diversion cases are addressed. A facility that identifies a diversion problem might bring in any combination of players, from private investigators and local law enforcement to state accreditation boards or the Drug Enforcement Administration (DEA). There is no overarching agency or organization that records every instance of drug diversion in the United States.” Lilly Chapa – The Dirty Little Secret of Drug Diversion

Don’t Forget!

Make sure you make your room reservations before the cut-off date to obtain NADDI pricing.

Refund Policy

All registrations are subject to NADDI’s Registration Deadline and Refund Policy.


Venue Website:

3800 American Boulevard East, Bloomington, Minnesota, 55425, United States

National Association of Drug Diversion Investigators Federal Tax ID: 52-1660752 / DUNS Number: 073539913

Copyright © 2022 - NADDI. All Rights Reserved. Privacy Policy / Trademark Policy / Copyright Policy / Refund Policy

Log in with your credentials


Forgot your details?

Create Account